In critically ill patients with COVID-19, antiplatelet therapy did not increase organ support-free days at 21 d.

Athale, Janhavi; Danner, Robert L

Athale, Janhavi; Danner, Robert L.

Athale J; Mayo Clinic Arizona, Phoenix, Arizona, USA (J.A.).
Danner RL; National Institutes of Health, Bethesda, Maryland, USA (R.L.D.).

Ann Intern Med ; 175(7): JC80, 2022 07.

Article in English | MEDLINE | ID: covidwho-1964535

ABSTRACT

ABSTRACT

SOURCE CITATION REMAP-CAP Writing Committee for the REMAP-CAP Investigators. Effect of antiplatelet therapy on survival and organ support-free days in critically ill patients with COVID-19 a randomized clinical trial. JAMA. 2022;3271247-59. 35315874.

Subject(s)

COVID-19; Critical Illness/therapy; Humans; Platelet Aggregation Inhibitors/therapeutic use; Respiration, Artificial; SARS-CoV-2

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Experimental Studies / Prognostic study / Randomized controlled trials Limits: Humans Language: English Journal: Ann Intern Med Year: 2022 Document Type: Article

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google